Core Viewpoint - The launch of the Tacrolimus extended-release capsules by Shiyao Group on JD Health represents a significant advancement in immunosuppressive therapy for organ transplant patients, offering a more convenient and stable treatment option [1][3]. Group 1: Product Launch and Features - The Tacrolimus extended-release capsules are designed to prevent transplant rejection in kidney and liver transplant patients, providing a safer and more effective immunosuppressive treatment [1]. - This new formulation allows for once-daily dosing, a shift from the traditional twice-daily regimen, which helps to stabilize drug concentration levels in the body and reduce the risk of side effects [3]. Group 2: Patient Benefits and Support - The extended-release formulation is expected to improve medication adherence and reduce patient burden, ultimately enhancing long-term treatment safety and protecting transplant kidney function [3]. - JD Health's comprehensive supply chain and online pharmacy services ensure that this specialized medication reaches patients efficiently and safely, while also offering online follow-up consultations and medication guidance [3]. Group 3: Future Plans - JD Health aims to collaborate with leading global pharmaceutical companies to introduce more innovative treatment options and provide a full spectrum of healthcare services, enhancing the quality of life for patients [4].

Core Viewpoint - The approval of Tacrolimus extended-release capsules by the National Medical Products Administration of China represents a significant advancement for the company in the immunosuppressive therapy market, enhancing its product portfolio in this area [1][2]. Group 1: Product Approval - The company has received a drug registration approval for Tacrolimus extended-release capsules (0.5mg, 1mg) from the National Medical Products Administration of China [1]. - Tacrolimus is an immunosuppressant that effectively inhibits the formation of cytotoxic lymphocytes responsible for transplant rejection [1]. Group 2: Indications and Mechanism - The product is indicated for the prevention of graft rejection after kidney and liver transplants, as well as for treating graft rejection that cannot be controlled by other immunosuppressive drugs [1]. - The mechanism of action includes the inhibition of T cell activation, proliferation of T helper cell-dependent B cells, and suppression of lymphokine production [1]. Group 3: Market Impact - The approval will further enrich the company's product line in the field of immunosuppressive therapy, positioning it for potential growth in this market segment [2].

Core Viewpoint - The approval of Tacrolimus extended-release capsules by the National Medical Products Administration of the People's Republic of China enhances the product line of the company in the field of immunosuppressive therapy [1] Group 1: Product Approval - The company has received a drug registration certificate for Tacrolimus extended-release capsules (0.5mg, 1mg) [1] - The product is considered to have passed the consistency evaluation of generic drug quality and efficacy [1] Group 2: Product Mechanism and Application - Tacrolimus is a macrolide immunosuppressant that inhibits the formation of cytotoxic lymphocytes responsible for transplant rejection [1] - The mechanism includes the suppression of T cell activation, proliferation of T helper cell-dependent B cells, and inhibition of lymphokine formation [1] - The product is indicated for preventing transplant rejection after kidney and liver transplants, as well as treating rejection that cannot be controlled by other immunosuppressive drugs [1] Group 3: Market Impact - The approval of this product will further enrich the company's product line in the field of immunosuppressive therapy [1]

自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 他克莫司緩釋膠囊獲藥品註冊批件 主席 蔡東晨 香港，2025年10月13日 – 1 – 石 藥 集 團 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）董 事 會（「董 事 會 」）欣 然 宣 佈，本集團開發的他克莫司緩釋膠囊（ 0.5 mg、1mg ）（「該產品」）已獲得中華人民共和國國家 藥品監督管理局頒發的藥品註冊批件，並視同通過仿製藥質量和療效一致性評價。 他 克 莫 司 是 一 種 大 環 內 酯 類 免 疫 抑 制 劑 ， 屬 於 鈣 調 神 經 磷 酸 霉 抑 制 劑 。 體 內 外 研 究 均 證 實，他克莫司具有強效的免疫抑制作用，能抑制引起移植物排斥反應的細胞毒淋巴細胞的 形成， ...